-
- Jean-Pierre J. Issa
- Authors' Affiliation: Department of Leukemia and Center for Cancer Epigenetics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
-
- Hagop M. Kantarjian
- Authors' Affiliation: Department of Leukemia and Center for Cancer Epigenetics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
説明
<jats:title>Abstract</jats:title> <jats:p>Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These old drugs, developed as cytotoxic agents and nearly abandoned decades ago were resurrected by the renewed interest in DNA methylation. They have now provided proof of principle for epigenetic therapy, the final chapter in the long saga to provide legitimacy to the field of epigenetics in cancer. But challenges remain; we don't understand precisely how or why the drugs work or stop working after an initial response. Extending these promising findings to solid tumors faces substantial hurdles from drug uptake to clinical trial design. We do not know yet how to select patients for this therapy and how to move it from life extension to cure. The epigenetic potential of DNA methylation inhibitors may be limited by other epigenetic mechanisms that are also worth exploring as therapeutic targets. But the idea of stably changing gene expression in vivo has transformative potential in cancer therapy and beyond.</jats:p>
収録刊行物
-
- Clinical Cancer Research
-
Clinical Cancer Research 15 (12), 3938-3946, 2009-06-15
American Association for Cancer Research (AACR)